KAPA.US Kairos Pharma, Ltd.

Healthcare Biotechnology USA Stocks
0.4536 USD
Close of Nov 15, 2026
0.4180 7.28
Market cap
USD 1.54M
P/E
-
P/B
0.37x
ROE
-172.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KAPA.US undervalued?

Graham number

The Graham number of Kairos Pharma, Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kairos Pharma, Ltd. fundamental analysis

No fundamental analysis for Kairos Pharma, Ltd. yet.

Kairos Pharma, Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kairos Pharma, Ltd.

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinic…

Full company profile